Gland Pharma Ltd
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
- Market Cap ₹ 30,834 Cr.
- Current Price ₹ 1,872
- High / Low ₹ 2,131 / 1,200
- Stock P/E 40.0
- Book Value ₹ 555
- Dividend Yield 0.96 %
- ROCE 11.9 %
- ROE 7.81 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 28.4%
Cons
- Stock is trading at 3.37 times its book value
- Company has a low return on equity of 9.22% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.04%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap Nifty Pharma
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|
2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 5,720 | |
1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,348 | 4,348 | |
Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,372 |
OPM % | 36% | 38% | 34% | 28% | 24% | 23% | 24% |
139 | 135 | 224 | 184 | 170 | 214 | 220 | |
Interest | 7 | 3 | 5 | 7 | 26 | 42 | 48 |
Depreciation | 95 | 99 | 110 | 147 | 345 | 378 | 387 |
Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,157 |
Tax % | 22% | 25% | 25% | 26% | 32% | 34% | |
773 | 997 | 1,212 | 781 | 772 | 699 | 770 | |
EPS in Rs | 49.88 | 60.94 | 73.75 | 47.42 | 46.90 | 42.40 | 46.75 |
Dividend Payout % | 0% | 0% | 0% | 0% | 43% | 42% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 8% |
TTM: | -2% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -17% |
TTM: | 7% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -10% |
1 Year: | 2% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 9% |
Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 |
5 | 5 | 5 | 4 | 372 | 314 | |
435 | 588 | 671 | 814 | 1,515 | 1,708 | |
Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 |
968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | |
CWIP | 188 | 338 | 191 | 177 | 238 | 151 |
Investments | 0 | 0 | 155 | 0 | 0 | 0 |
2,929 | 5,204 | 5,986 | 7,030 | 6,426 | 6,875 | |
Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
701 | 605 | 791 | 364 | 997 | 915 | |
-761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | |
-7 | 1,238 | 35 | 15 | -799 | -433 | |
Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 83 | 71 | 89 | 88 | 100 | 99 |
Inventory Days | 250 | 312 | 205 | 421 | 278 | 294 |
Days Payable | 82 | 97 | 80 | 127 | 129 | 143 |
Cash Conversion Cycle | 251 | 286 | 214 | 382 | 250 | 250 |
Working Capital Days | 161 | 169 | 168 | 242 | 155 | 173 |
ROCE % | 28% | 25% | 15% | 14% | 12% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Outcome of AGM 28 Aug
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 28 Aug
-
Announcement under Regulation 30 (LODR)-Change in Directorate
28 Aug - Reappointment of Mr. Essaji Goolam Vahanvati as independent director for five years from 30.09.2025; commission approved.
-
Announcement under Regulation 30 (LODR)-Change in Management
28 Aug - Shareholders approved M/s RVR & Associates as secretarial auditors for five-year term from 47th AGM on Aug 28, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
26 Aug - USFDA approval for Vasopressin 5% Dextrose 40U/100mL RTU; tentative 20U/100mL approval; product sold ~$45M year to June 2025.
Annual reports
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
Product Portfolio
The company is one of the largest and fastest-growing injectable-focused companies, providing 89+ product SKUs, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, across 15+ therapeutic areas. [1] [2]
The company launched 85 new molecules between FY22 and FY24, and introduced 12 new molecules, including Cetrorelix Acetate, Tranexamic Acid, Eribulin mesylate, Plerixafor, Nelarabine, etc., in the US market during H1 FY25. [3] [4]